>>> biogen issued the ice bucket challenge to cnbc. will anybody accept?et us who you'd like to see get soaked for a good cause. >>> back-to-school season. should williamson nome ma be on the must buy list? we'll find out why when the analyst who made the call joins us next. >>> trade-off series come full circle, to me. what traders do when they're not trading. find out what i do when i'm not being the judge. ♪ when the world moves, futures move first. learn futures from experienced pros with dedicated chats and daily live webinars. and trade with paper money to test-drive the market. all on thinkorswim from td ameritrade. i make a lot of purchases foand i get ass. lot in return with ink plus from chase. like 50,000 bonus points when i spent $5,000 in the first 3 months after i opened my account. and i earn 5 times the rewards on internet, phone services and at office supply stores. with ink plus i can choose how to redeem my points. travel, gift cards, even cash back. and my rewards points won't expire. so you can make owning a business even more rewardin

john: you worked with a company, biogen, a picture of the board with wearing their beanie hat.is turned your head? >> this folks wearing beanies they were world class scientists nobel prize winners, wok individua-- oneindividual in pat died last year, ken murray, and his work led to what is now the hepatitis va vaccine, and this s hugely important. >> the way he was paid, is now forbidden, he got stock options that is now illegal? >> that is correct. if he does research he did, to develop the hepatitis vaccine, he could not have had the stock, he would not have done it. john: thank you, tom, and next, just what is this show about? why are there so many stossels here? i will try to tie this together. next. unlimited cash back. let that phrase sit with you for a second. unlimited. as in, no limits on your hard-earned cash back. as in no more dealing with those rotating categories. the quicksilver card from capital one. unlimited 1.5% cash back on everything you purchase, every day. don't settle for anything less. i'll keep asking. what's in your wallet? i'll keep asking. when fol

john: you worked with a company, biogen, a picture of the board with wearing their beanie hat.is turned your head? >> this folks wearing beanies they were world class scientists nobel prize winners, wok individua-- oneindividual in pat died last year, ken murray, and his work led to what is now the hepatitis va vaccine, and this s hugely important. >> the way he was paid, is now forbidden, he got stock options that is now illegal? >> that is correct. if he does research he did, to develop the hepatitis vaccine, he could not have had the stock, he would not have done it. john: thank you, tom, and next, just what is this show about? why are there so many stossels here? i will try to tie this together. next. when folks think about what they get from alaska, they think salmon and energy. but the energy bp produces up here creates something else as well: jobs all over america. engineering and innovation jobs. advanced safety systems & technology. shipping and manufacturing. across the united states, bp supports more than a quarter million jobs. when we set up operation in one part o

john: you worked with a company, biogen, a picture of the board with wearing their beanie hat.his turned your head? >> this folks wearing beanies they were world class scientists nobel prize winners, wok individua-- oneindividual in pat died last year, ken murray, and his work led to what is now the hepatitis va vaccine, and this s hugely important. >> the way he was paid, is now forbidden, he got stock options that is now illegal? >> that is correct. if he does research he did, to develop the hepatitis vaccine, he could not have had the stock, he would not have done it. john: thank you, tom, and next, just what is this show about? why are there so many stossels here? i will try to tie this together. next. fighting constipation by eating healthier, drinking plenty of water, but still not getting relief? try dulcolax laxative tablets. dulcolax is comfort-coated for gentle, over-night relief. dulcolax. predictable over-night relief you can count on. beautiful, awesome, messy kids. they get stains like you wouldn't believe. this new tide ultra stain release & zap cap helps me get

john: you worked with a company, biogen, a picture of the board with wearing their beanie hat. this turned your head? >> this folks wearing beanies they were world class scientists nobel prize winners, wok individua-- oneindividual in pat died last year, ken murray, and his work led to what is now the hepatitis va vaccine, and this s hugely important. >> the way he was paid, is now forbidden, he got stock options that is now illegal? >> that is correct. if he does research he did, to develop the hepatitis vaccine, he could not have had the stock, he would not have done it. john: thank you, tom, and next, just what is this show about? why are there so many stossels here? i will try to tie this together. next. in new york state, we're changing the way we do business, with startup ny. we've created tax free zones throughout the state. and startup ny companies will be investing hundreds of millions of dollars in jobs and infrastructure. thanks to startup ny, businesses can operate tax free for 10 years. no property tax. no business tax. and no sales tax. which means more growth for

john: you worked with a company, biogen, a picture of the board with wearing their beanie hat.head? >> this folks wearing beanies they were world class scientists nobel prize winners, wok individua-- oneindividual in pat died last year, ken murray, and his work led to what is now the hepatitis va vaccine, and this s hugely important. >> the way he was paid, is now forbidden, he got stock options that is now illegal? >> that is correct. if he does research he did, to develop the hepatitis vaccine, he could not have had the stock, he would not have done it. john: thank you, tom, and next, just what is this show about? why are there so many stossels here? i will try to tie this together. next. we never thought we'd be farming wind out here. it's not just building jobs here, it's helping our community. siemens location here has just received a major order of wind turbines. it puts a huge smile on my face. cause i'm like, 'this is what we do.' the fact that iowa is leading the way in wind energy, i'm so proud, like, it's just amazing. that, my friends, is everything. and with the qu

meg was up at biogen in massachusetts. they did it with the entire als team. kudos to meg as well. deserves a lot of credit for doing it herself and the good folks add biogen for doing it. >> i hope cnbc wardrobe has sent her a change up there. >> they delivered me a dry golf shirt. >> mr. zuckerberg we're waiting, we're available. we've all got facebook pages, would love to hear from you. >> we'll see what he responds, if anything. >> fantastic. thank you very much. >>> orange juice prices spiking this week. what's behind the big move? i know you've been wondering this. it has been an icon -- i have a closet full. are we see the death of denim? i'm probably the indicator. >> fashion is fickle, but this trend towards so-called at leisure is only gaining steam. some experts say it would be here to say. we'll tell you what the experts say and who might be most exposed, coming up on "power lunch." ohn's disease is tough, but i've managed. i got to be pretty good at managing my symptoms, except that managing my symptoms was all i was doing. when i finally told my doctor, he said my cro

i want to make sure you and your partnership with say, biogen isn't going to sell me a drug that's bads, it's believable. >> well, it's superficially plausible. people cheat for money. but the fact is that it takes enormous amounts of resources to get those products to people. medicine's incredibly better today than when i started out. and it's too bad that the medical products industry, the drug companies, the device companies have let themselves be blamed for bad things they didn't do. and they've let doctors, hospitals, medical journals, medical schools take credit for the good things they've done. now, all those things are important. >> yeah, i thought that's where the innovation came from. from medical schools and government-funded research. >> well, i've had government funded research my whole life. it's great, it's important. but the vast predominance of what gets products to patients comes from the private sector. only a private sector has the resources and the skill sets to get the job done. >> and the experiment that taught you that is you ended up working with this company b

. >> i watched biogen, celgene, regeneron, these companies keep winning, biogen, new m.s., gill add lookike defeated patent challenge, regeneron, the drug works well with statin. btk, incredible. it's where the stake is. btk. >> you made the point on friday night, i believe, you've got to know when to ring the register, right? if you had some big gains, you can't fault people for seeing headlines and all of the stuff, it's time to take stuff off the table. >> i'm doing all oil on "mad money" stocks have fallen so bad. you did have to ring the register, oil did collapse. if oil stabilizes, 95, those stocks are going to be good. we see buyers coming in, schlumberger, last time we heard schlumberger, 118 target then the stock goes down. ringing the register in oils was good but you might have to circle back to stuff that go overly rung from the register. >> you'll talk about energy. you had a leadership group, stocks doing well, sold off. some peep people talking about maybe there's a circle. >> you have go back. >> to that sick ter. >> nat gas, it's cool. i thought i ought to have a coat o

with compassion et use requests pouring in, biogen prepared enough supply to give 5,000 patients if the drug proved to work in clinical trials. >> an individual situation while difficult and heart wrenching has to be weighed against the backdrop of what the ultimate goal is which is to bring these drugs to market to treat the cross section of the population as quickly as we can possibly do it. >> reporter: there are risks for both patients and drug makers. natalee's doctor worried about the safety. >> these drugs are not ben nine. i have concerns about using potentially using a medication that we have no information on because of side effects can be very serious. potentially life threatening. >> reporter: the companies worry about side effects. art caplin advised drug makers on compassionate use. >> people who take experimental drugs are often sick. the odds of getting better are rare. >> reporter: there is bad outcome in a patient much sicker than others could affect the drug's chances of approval and another factor they must consider, supply. >> they might have as much as a tiny thimb

and biogen is working on that actually. >> do you know -- >> it affects the nerves and the brain andpinal cord which is where the nerves are. but also what biogen is doing a huge genome sequencing project trying to figure out what is causing this. >> go backwards. find out where the anomalies are and the geno type for people that actually come up with because it's not strictly hereditary. >> right. >> it may run in families. >> but they don't know. one thing that's kind of odd about it is it does seem to strike folks who are very active athletically. they don't know if there's a real correlation there. but you just see that a lot very athletic people, they -- >> look how long stephen hawking -- >> that's true it's very different -- >> and you can get it when you're old. my mother got it when she was like 84 years old. >> oh, gosh. >> and when you're 84, i mean it's a scary way to go, because you feel helpless. but the life years loss compared to someone 29 or 30 years old, it's not -- you don't look at it the same way. even cancer should be expressed not if you kill someone who is 95

biogen is working hard in the space.a couple hours by a few dozen other researchers to take the challenge involving a couple dozen of these dumped on their heads. we'll see that. this is a challenge that's swept the nation. president obama has been issued a challenge. we'll see if he takes it. the als association says they raised 2.3 million from this since july 29th when it began. that compares with $25,000 raised in the same period last year. this is raising awareness and funds. back do you. >> are you going to do it? >> reporter: we shall see if i'll do it, and we'll see if your favorite cnbc faces might take part in the challenge. check that out on "halftime report" later. >> what? on your show? >> yeah. >> did you know this? >> no. >> uh-oh. >> dude, are you going to get wet? >> getting out of here now. >> is that why you spilled the water? >> thanks. >> yeah, thank you. >> reporter: thank you, guys. >> 60 years since lou gehrig gave the speech, and they got every first baseman to read part, and finally showed -- my

i see biogens as well. >> this was a stock trading basically $500 in march, had a huge pullback to 220 or. so when she talks about 100% upside. that's not that crazy. i know it seems nuts, look at the stock, extraordinarily volatile. about a 10% short interest. interesting name in a space. this isn't that crazy. it is a binary play. i think you are probably 75-25 it works. >> as you mentioned it went up to $500 bucks. >> 447, yes. >> when you say for the average investor, what is the risk? if one of these things fails or one outsources or outsizes its competition then the rest gets slammed. >> are you still hurting. >> did you feel the pain? >> yes. >> did you see me wince? so for me, put the stock, it's up right now. >> so grasso bought clovis. it was a bad trade. you are burned. >> hi, my name is steve grass so. i bought clovis. >> i am still long clovis. it's 31% off the bottom. if you are a home gamer, you buy the ibb. or you put parameters in or trade with pete. >> the posterboy for biotechs. >> big boy. our traders told you what to buy, now they will tell you what stocks to get r

company was working on a therapy for lou gehrig's disease, with compassionate use requests pouring in, biogen prepared enough for 500 patients. >> in an individual situation, while difficult and heart wrenching, it has to be weighed against the backdrop of the ultimate goal, which is to try to bring these drugs to market to treat the broadest cross-section of a population as quickly as we can possibly do it. >> reporter: there are risk for both patients and drug makers. natalie's doctor worries about the safe of an unproven medicine. >> these drugs are not benign. i certainly have concerns about using -- potential using a medication that we have no information on, because the side effects can be very serious, potential life-threatening. >> the companies also worry about side effects. bioethicist kaplan has been advised. >> the odds of them getting better are tiny. it happens, but it's rare. >> reporter: there's a concern that a bad outcome in a patient much sicker could affect a drug's chances of approval. another factor -- summer. >> they might have as much as a tiny them able full of that d

coming up, a team at biogen accepts the challenge and gets soaked for the cause.n a bit. >> we'll watch to see if you get involved as well, scott. >>> that's coming up on "the half." >>> and between amazon and disney, reporting amazon stopped taking pre-orders to numerous disney movies including "capital america: the winter soldier" now the standoff is about more than pricing. the journalist says the fight encompasses placement and places on amazon websites as well as who makes up the difference when amazon loses money to match the price of competitors. jon, the big question continues to be, how much does amazon need more money from its partners and vendors to fund some of its forays into other ventures? >> kay ley, still sounds like price to me when it comes down to it. retailers having discussions with supplier over an online equivalent of an end cap. comes down to how much of the money do i get to keep at the end of the day for selling this thing you provide? >> still the discussion continues. we talk about it every day now, that because they are forced to resp

. >> biogen. he will be in there until they spin it. i think when they spin it, it's north of 70. >> tesla has an outperform rating. the analyst behind the calls joins us on the "fast" lean, andrew, great to havef to have you with us. make a point it will be a niche part of the global automobile or vehicle industry but it's going up to u up 32% through 2020, which is staggering. how do you get to this projectio projection? >> sure, thanks, for having me on. tesla 5% in the global market. reset doubles next year with the launch of the model x and gre to 400,000 units by 2020. really, this will be driven by lower battery costs. we don't see it being an issue, seeing with experts, we see this as very much achievable and tesla is able reach a larger adjustable mark, we see significant growth opportunity. >> you see the ed market share with a full launch of the ge n3 vehicle coming up smplt this akooum seuming the other auto makers won't come near with tesla? >> no, we believe that bmw will be a serious market, the i3 is a good product and a

celgene, gilead, biogene, regeneron, all great names still despite the move they had. >> hot ipo mobileeye getting a boost today. it comes after a few banks have positive ratings. we followed it earlier today. a buy rating at a $48 price target was stuck on it. eli, thank you for being with us. >> thank you for having me. >> you have an forecast of 67%. you say there could be upside. analysts are so bullish. what would that upside be to a 67% forecast? >> so, mainly, the 67% forecast essentially assumes that actor safely will perform the same way we seen seatbelts, airbags and electronic stability control in the past. we seen this penetration in the past. where we think we are being conservative, we are not assuming any close margin expansion out there, even though the company's next generation of products will be of higher asp and pricing as safety into autonomous capability t. you a on the pus market is two to three times with higher margins. we think the upside there. our 2025 revenue over 3 billion is over consensus, it's over the market of $15 billion plus. >> you believe there is act

the guy at biogen nominated meep, and you can see pete najarian was all too happy toe oblige.llenged twitter ceo dick costolo, and carl quintanilla and just posted a vine. take a look. >> i accept scott's challenge to stomp out als. >> there he is. costolo good sport. responded within i don't know, ten minutes. said he would do it and challenge our own carl quintanilla do to itacy well who just stepped um to the plate outside the new york stock exchange. let's take a look at carl. >> i accept the challenge. >> yeah, carl ap good sport. i kind of roemped him into that pap great sport. carl, also making his own nominations for the challenge, and get this. these are good ones. he's asking -- warren buffett -- john legere, from t-mobile, obviously and bezos. jeff bezos. now, those are great ones. >> they are. >> one of the three will take it, is my prediction i. think two take it. >> legere will take it. t-mobile that guy will do -- >> the wild card is bezos. >> you would think bezos would deliver on the pledge in the same day? >> within two days. >> had a drone drop the water --

today's ipos, macro cure and vascular biogen cancer therapy, down about 1 percent.p up with this, according to the markets, still had eight health care ipos, largest ipo count for this sector since 2001, and by the way, there have been standouts. look at loco, el poll lo loco, mexican fast food chain, up. you discussed mobileye. another standout. back to you. >> all right, seema, thanks. >>> coming up, some unusual activity in the chip space. jon najarian is all over it and how he's trying to profit from it as well. that and much more, straight ahead. >>> busy interesting day to kickoff august coming up apartment the top of the hour or "power lunch," we hope you'll join us. putting on my glasses. stocks sliding after yesterday's big sell-off. time to short the market? ron insana says, yes. we'll ask lew ahow and why he'sg it. >>> and first month down since april. worst monthly loss in more than two years. what does it signal? what should you do? now back to scott and the "fast money/half time" group. >>> back to david faber on the floor of the new york stock exchang

celgene, gilead, biogen. it's up about 1% in today's trade.ow, outside of biotech, apple still has the largest room here on the nasdaq, steadily rising over the past one week ahead of its iphone 6 launch. in fact, rbc notes that most supply chain data indicates that apple is gearing up for 70 million to 80 million iphone 6 units which is a substantial increase from last year's ramp of 50 million to 60 million units. so apple up about 1%, nearing the $100 mark, scott. >>> let's trade some of these names that have been rocking the nasdaq. >> absolutely. >> this year. >> yeah. >> what do you like? >> i was just going to say look at the risk appetite and how many times did we talk about that over the last couple of weeks. a market that's getting hit even and yet the risk appetite is out there. look at tesla, netflix moving to the upside. look at amazon bouncing off some of those lows off of support levels. so you're seeing a lot of this. and then the solar names they've been picking up steam over the last couple weeks as well. gtat, a name that's

"the wall street journal" says sales of vascular biogenic score shared for six days, but these salese a key investor act out. that is your company news. >> thank you, olivia. thistime for a little matters now. >> thank you, adam. this matters not to our guest host, tobias levkovich of citigroup. a set of cash flows, tax do not shake., it is an immediate $12 billion improvement. one indication of the incredible treasure on corporate leaders to engineer cash back to shareholders. it is a whole new twist, tobias. share repurchase, m&a -- maybe we should invest, now we have financial engineering. >> well, financial engineers have been going on for almost as long as i have been in the business. i think you are seeing more interestingly is a bit of a shift away from the dividend and the stock buyback program to more m&a and capital spending stop. they are using cash, but they are using it in ways to grow their businesses, more so than just shrinking and returning cash to shareholders. >> which sector is more interesting here? media, pharmaceutical, corporate version -- which sector has you

biogen, all still doing well. >> if you look at the best-performing group, financials.rprised to see that. >> the european banks were strong, though. >> right. >> that's very good point. >> whether it's a bailout or a bail-in, they took it on the chin. the holders of the senior debt, they remained whole, so to speak. >> they did not have a good number. the bank was only supposed to do well when we see higher rates. it's interesting. let's see if that continues. it would be a leadership group. >> treasury prices are stronger, yields are lower. >> let's look at the social media names moving. typically a pretty good gauge of risk. yelp reported earnings last week. it was not a universal theme here. yelp is under more pressure. that company is having trouble, stumbles in the latest quarter. >> i look at both gross margins and also local media on aggregate. the thing that people have to worry about when you sell or short y echlelp, they all want n you. you can short it until the cows come home. he's a smart guy. yelp is the yellow pages with qualitative commentary. >> and th

. >> unbelievable the list, gilead, celgene, regeneron, amgen, biogen, top ten. >> new valuations onunsung hero of the period, the regeneron ceo, when "mad money" started we couldn't get ceos to come on. heed hey $5 stuock, he had a formulation. this amazing drug, for macular degeneration, a winner. they've got other things in the fire. you start getting a company, you say, wow, that's multiple billion of dollars but you think, wait a second. if intermune is a bolt on for $8 billion, is what sanofi if they want to buy regeneron? regeneron, i like alone, it's doing so well. celgene, no one's going to buy celgene, it's too big. gilead, it's too big. look out, merck. look out, pfizer. they're coming to get you. >> we'll get stop trading with jim. s&p 1998.5 now. "squawk on the street" will be right back. we do? i took the trash out. i know. and thank you so much for that. i think we should get a medicare supplement insurance plan. right now? [ male announcer ] whether you're new to medicare or not, you may know it only covers about 80% of your part b medical expenses. it's up to you to

biogen. smith kline, johnson & johnson. institutionally these are all shareholder sponsored entities who all are going to be very inte in ging and not 25 years of research back where all these institutions coming into play they are only interested in the clinical application of what they find. and for a lot of the people i ever sure that is what they are most focused on. >> center, i appreciate your raising because i am personally very excited about this port is close to three years and to try to build momentum and was thrilled that it was possible to announce this just a couple of weeks ago. it is unprecedented to have nih and academic researchers getting together around the same table with equal financial contributions with and pharmaceutical companies to say this is our problem. let's work on it together, and with an agreement that all the data will be publicly accessible so we are calling this no longer competitive part of the process. the opportunities now because of the proliferation of discoveries about basic science